This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer (ICOG)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by Iwate Medical University.
Recruitment status was:  Recruiting
Information provided by:
Iwate Medical University Identifier:
First received: July 5, 2007
Last updated: July 30, 2008
Last verified: July 2008
The purpose of this study is to conduct a randomised controlled trial (RCT) comparing UFT/LV and UFT/LV + PSK in patients with histological stage IIIa/IIIb colorectal cancer who have undergone curative surgery without residual cancer using 3-year disease free survival (DFS) as the primary endpoint, and also to analyze the 3-year overall survival (OS), compliance, adverse events, quality of life (QOL) and relationship with tumor factors.

Condition Intervention Phase
Colorectal Cancer Drug: UFT, Calcium Folinate, PSK Drug: UFT, Calcium Folinate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by Iwate Medical University:

Primary Outcome Measures:
  • Disease-free survival [ Time Frame: 3-years ]

Secondary Outcome Measures:
  • Overall survival, compliance, adverse events, QOL, tumor markers [ Time Frame: 3-years ]

Estimated Enrollment: 300
Study Start Date: July 2007
Estimated Study Completion Date: May 2013
Arms Assigned Interventions
Active Comparator: 1
The Control Group (UFT + Calcium Folinate)
Drug: UFT, Calcium Folinate
Experimental: 2
The PSK Group (UFT + Calcium Folinate + PSK)
Drug: UFT, Calcium Folinate, PSK

Detailed Description:
To conduct a randomized controlled trial comparing chemotherapy using UFT/LV and immunochemotherapy using UFT/LV combined with PSK in patients with histological stage IIIa and IIIb colorectal cancer (adenocarcinoma) who have undergone curative surgery without residual cancer (R0) using 3-year disease-free survival rate as primary endpoint, and also to analyze the 3-year overall survival, compliance, adverse events, QOL and relationship with tumor factors.

Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with a histological diagnosis of primary colon or rectal cancer (adenocarcinoma)
  • Patient with histological stage IIIa or IIIb cancer (according to the Japanese Classification of Colorectal Cancer, 7th edition)
  • Patient who has undergone curative surgery with no residual cancer
  • Pretreatment criterion: patient who has not undergone preoperative cancer treatment (radiotherapy, chemotherapy or immunotherapy)
  • Patient who is at least 20 years and below 80 years of age
  • Patient with performance status (PS) of 0-1 (according to Eastern Cooperative Oncology Group, ECOG)
  • Restrictions of concomitant medications and therapies: except in the case of metastasis or recurrence, concomitant use of other chemotherapeutic and immunotherapeutic agents that may affect the results of this trial, and concomitant use of radiotherapy are prohibited in principle.
  • Organ function (laboratory data): patient who satisfies the following conditions or data of laboratory tests conducted within 2 weeks prior to start of trial

    • Gastrointestinal function: no diarrhea (watery stool)
    • White blood cell count: > 4,000/mm3
    • Platelet count: > 100,000/mm3
    • Serum GOT and GPT: < 100 IU/L
    • Serum total bilirubin: < 2.0 mg/dL
    • Serum creatinine: below the upper limit of facility normal range

Exclusion Criteria:

  • Patient with residual cancer (R1 or R2)
  • Patient with anal canal lesion (P) or perianal skin lesion (E)
  • Patient with stricture and not capable of oral intake
  • Patient passing fresh blood from the gastrointestinal tract
  • Patient with retention of body cavity fluid necessitating treatment
  • Patient with infection, intestinal palsy or intestinal occlusion
  • Patient with active multiple cancers or patient who has less than 5 years of remission from a metachronous cancer (except carcinoma in situ and skin cancer)
  • Patient who is pregnant or wishes to become pregnant during this trial
  • Patient on continuous insulin treatment for diabetes or has poorly controlled diabetes
  • Patient with a history of ischemic heart disease and judged to have difficulties to participate in this trial
  • Patient with concurrent psychiatric disease or neurological symptoms and judged to have difficulties to participate in this trial
  • Patient on continuous steroid therapy
  • Patient with a history of serious drug allergy
  • Patient who is judged for other reasons by the investigator or doctor in charge to be inappropriate as a subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00497107

Contact: Go Wakabayashi, MD, PhD +81-19-651-5111

Iwate Medical University Hospital Recruiting
Morioka, Iwate, Japan, 020-8505
Contact: Koki Otsuka, MD    +81-19-651-5111 ext 3627   
Principal Investigator: Go Wakabayashi, MD, PhD         
Sub-Investigator: Koki Otsuka, MD         
Sponsors and Collaborators
Iwate Medical University
Study Director: Go Wakabayashi, MD, PhD Iwate Clinical Oncology Group
  More Information

Publications: Identifier: NCT00497107     History of Changes
Other Study ID Numbers: ICOG-CC01
Study First Received: July 5, 2007
Last Updated: July 30, 2008

Keywords provided by Iwate Medical University:
Colorectal cancer
Adjuvant therapy

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Calcium, Dietary
Bone Density Conservation Agents
Physiological Effects of Drugs
Protective Agents
Vitamin B Complex
Growth Substances processed this record on June 23, 2017